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Abstract
Introduction: Nowadays, on-a-chip capillary electrophoresis is a routine method for the detection of PCR fragments. The Agilent 2100 Bioanalyzer 
was one of the first commercial devices in this field. Our project was designed to study the characteristics of Agilent DNA 1000 kit in PCR fragment 
analysis as a part of circulating tumour cell (CTC) detection technique. Despite the common use of this kit a complex analysis of the results from a 
long-term project is still missing. 
Materials and methods: A commercially available Agilent DNA 1000 kit was used as a final step in the CTC detection (AdnaTest) for the determi-
nation of the presence of PCR fragments generated by Multiplex PCR. Data from 30 prostate cancer patients obtained during two years of research 
were analyzed to determine the trueness and precision of the PCR fragment size determination. Additional experiments were performed to demon-
strate the precision (repeatability, reproducibility) and robustness of PCR fragment concentration determination.
Results: The trueness and precision of the size determination was below 3% and 2% respectively. The repeatability of the concentration determi-
nation was below 15%. The difference in concentration determination increases when Multiplex-PCR/storage step is added between the two mea-
surements of one sample.
Conclusions: The characteristics established in our study are in concordance with the manufacturer’s specifications established for a ladder as a 
sample. However, the concentration determination may vary depending on chip preparation, sample storage and concentration. The 15% variation 
of concentration determination repeatability was shown to be partly proportional and can be suppressed by proper normalization.
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The Agilent 2100 Bioanalyzer is an on-a-chip capil-
lary electrophoresis system. It represents a perfect 
compromise in DNA separation methods. It is a 
bench-top device which is smaller and less expen-
sive than classic capillary electrophoresis. It is easi-
er to handle and more time-efficient than agarose 
gel electrophoresis (1,2). Moreover, the Agilent 
2100 Bioanalyzer provides both size and concen-
tration determination of PCR fragments. For these 
reasons the Agilent 2100 Bioanalyzer has estab-
lished a place in many molecular biology applica-
tions (3-6). 
Despite the frequent research use of the Agilent 
2100 Bioanalyzer, only a few papers exist which fo-
cus on the technical aspects of this device or dis-
cuss its characteristics in specific applications. Ba-
sic statistical data for well-to-well, chip-to-chip 
and day-to-day measurements were summarized 
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by Panaro et al. They used commercially available 
DNA fragments and PCR products for the evalua-
tion of the characteristics of the DNA 7500 Lab-
Chip (7). Later on, the accuracy and reproducibility 
of DNA fragment measurements on the DNA 500 
LabChip were assessed by Jabasini et al. (8). 
Throughout the years, the characteristics of meas-
urements on the Agilent 2100 Bioanalyzer have 
been published in works presenting its usage in 
new applications (9-12). 
The Agilent DNA 1000 kit can be used as a final 
step in the determination of circulating tumour 
cells (CTC) in the blood of patients with castration-
resistant prostate cancer made by AdnaTest tech-
nique. The final result of this analysis depends on 
the presence of PCR fragments of the expected 
size in a concentration above the threshold given 
by the manufacturer (13). The aims of this study 
were i) to evaluate the data obtained during two 
years of CTC research made by this technique and 
ii) to establish the characteristics of the method 
used for the PCR fragment detection. The trueness 
and precision of PCR fragment size determination 
by the Agilent DNA 1000 kit in this specific applica-
tion will be determined based on the data collect-
ed in the first phase of the study. Moreover, addi-
tional experiments will be performed to deter-
mine the precision (repeatability, reproducibility) 




The study describes the PCR fragment size and 
concentration determination performed with the 
commercially available Agilent DNA 1000 reagent 
kit (Agilent Technologies, USA, Santa Clara) on the 
2100 Bioanalyzer (Agilent Technologies, USA, San-
ta Clara). The blood of 33 castration-resistant pros-
tate cancer patients was analyzed at the time of 
diagnosis and in the course of therapy (altogether 
60 samples) to determine the CTC presence by Ad-
naTest (AdnaGen, Germany, Langenhagen). Ob-
tained data were used for the evaluation of the 
Agilent DNA 1000 kit and 2100 Bioanalyzer prop-
erties. The study was approved by the Ethics Com-
mittee of the General University Hospital in 
Prague. All the patients signed their written in-
formed consent to participation in the study. 
Methods
All of the samples were prepared through use of 
the AdnaTest ProstateCancer Select and Detect 
kits for the detection of CTCs. Every step was made 
according to the manufacturer’s protocol (13,14). 
CTCs were enriched from 5 mL of whole (EDTA) 
blood by magnetic beads coated with anti-EpCAM 
and anti-HER2 antibodies. Immunomagnetically 
separated mRNA from CTCs’ enriched fraction was 
reversed transcribed to cDNA. Subsequently, there 
occurred Multiplex-PCR (Multi-PCR) with the prim-
ers for internal control (Actin-120 bp) and epitheli-
al/prostate-specific markers (Epidermal growth 
factor receptor (EGFR)-163 bp, Prostate specific an-
tigen (PSA)-357 bp, Prostate specific membrane 
antigen (PSMA)-449 bp). The presence and con-
centration of PCR products were evaluated by the 
reagent kit Agilent DNA 1000 on 2100 Bioanalyzer. 
If at least one of the PCR fragments was of a higher 
concentration than 0.30 ng/µL the sample was 
evaluated as CTC positive, concentration between 
0.15-0.30 ng/µL was evaluated as borderline and a 
concentration of under 0.15 ng/µL was evaluated 
as CTC negative. The cDNA and PCR products from 
each sample were stored at -20 °C to allow for a re-
peat of the analysis. The positive controls used in 
the experiments were part of the AdnaGen Pros-
tateCancerDetect kits. They contained the DNA of 
all four monitored genes.
The detection of the PCR fragments takes place on 
disposable chips which consist of a plastic cover 
with 16 wells and a glass chip. The fragment sepa-
ration takes place in the channels micro fabricated 
into the glass chip which is filled with a gel/dye 
mixture before the analysis. The fluorescent inter-
calating dye enables the detection of the PCR frag-
ments by a semiconductor laser (630 nm) integral 
to the 2100 Bioanalyzer (5). The maximum capaci-
ty per chip is 12 samples. The remaining four wells 
placed on the chip serve as a ladder well, priming 
well, gel/dye reserve and waste well. All the sam-
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ple wells and the ladder well are filled with the 
Marker mix (internal control) into which 1 µL of 
sample or ladder is added (15-17). The presence of 
internal markers (lower marker 15 bp, 4.2 ng/µL; 
upper marker 1500 bp, 2.1 ng/µL) in each well ena-
bles a comparison of results even between differ-
ent chips. The size of PCR fragment is determined 
from the molecular size ladder which is measured 
on each chip. The quantification of the fragments 
is based on the comparison of the peaks with the 
upper marker which is measured in each well (15).
The Agilent DNA 1000 Kit designed for the analysis 
of DNA fragments from 25-1000 bp was used in 
our work. Manufacturer’s specifications for the size 
determination accuracy and reproducibility of this 
product are relative standard deviation (RSD) of 
10% and 5% for a ladder as a sample, respectively. 
The specifications for the concentration determi-
nation accuracy and reproducibility are 20% RSD 
and 15% RSD for a ladder as a sample, respectively 
(17). The whole procedure from the CTCs selection 
until chip preparation was conducted in the lami-
nar hood. Positive and negative controls from Mul-
ti-PCR and negative control from RT were run on 
each chip. From one to nine samples were meas-
ured in the remaining wells. A dsDNA 1000 setting 
was used in 2100 Expert software (Agilent Tech-
nologies, USA, Santa Clara). 
The results of the size determination of all four PCR 
fragments (Actin, EGFR, PSA, PSMA) from all the 
measurements performed during the two years of 
the CTC project were recorded. All together, 31 
positive control and 101 patient sample measure-
ment were performed in the study. However, not 
all patient samples contained all monitored frag-
ments. Actin as a control fragment present in each 
measurement was measured 101 times, EGFR 15 
times, PSA 69 times and PSMA 31 times. The num-
ber of measurements is higher than the total num-
ber of the patient samples since some of the sam-
ples were measured several times. The additional 
experiments exploring the repeatability, repro-
ducibility and robustness of the concentration de-
termination of the Agilent DNA 1000 kit on the 
2100 Bioanalyzer were performed. The outline of 
these experiments is depicted in Figure 1. 
Statistical analysis
The averages and the standard deviations (SD) of 
PCR fragment size and concentration determina-
tion were calculated. Relative standard deviation 
(RSD) was calculated as a quotient of SD divided by 
the average of PCR fragment size/concentration:
RSD [%] = (SD / Average) × 100.
Average RSD was calculated in those cases in 
which more measurements of samples/controls in 
appropriate conditions were taken for example for 
PCR fragment concentration repeatability, repro-
ducibility and robustness determination. The RSDs 
of all PCR fragments from each sample/control 
measurement were taken and the average RSD 
and its SD were counted to show the overall varia-
bility between the measurements.
For a better comparison of the results between 
chips the absolute values of the concentration of 
each PCR product in the sample was used. The 
concentration of each fragment was normalized 
by dividing its actual concentration by the sum of 
concentrations of all fragments measured in the 
sample (well). The normalization of the concentra-
tions for all fragments was calculated by the for-
mula: 
Cnormalized = CActin/EGFR/PSA/PSMA/ 
(CActin + CEGFR + CPSA + CPSMA).
Statistical functions from Microsoft Office Excel 
2007 were used for the calculations. 
Results
The precision and the trueness of PCR 
fragment size determination
The precision and trueness of PCR fragment size 
determination were determined based on all four 
PCR fragment size measurements collected during 
the two years of CTC research. The evaluated data 
are presented in Table 1. The results from patient 
samples and positive controls are evaluated both 
separately and altogether. The RSDs for the size 
determination of the PCR fragments did not ex-
ceed 2%. 
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Figure 1. A scheme of the experiments investigating the characteristics of the concentration determination by the Agilent 1000 DNA 
kit on the 2100 Bioanalyzer.
a) Repeatability: One positive control stored at -20°C after Multi-PCR was slowly thawed, vortexes and briefly spun down. One µL was 
put into each of the twelve wells on one chip. 
b) Robustness: 1) Sample volume changed: 0.8 µL; 0.9 µL; 1.0 µL; 1.1 µL; 1.1 µL; 1.0 µL; 0.9 µL; 0.8 µL of one positive control was put 
into wells number 1, 2, 3, 4, 5, 6, 7, 8 on one chip instead of the standard 1 µL respectively. The measurement was repeated three 
times on different chips. 2) Marker mix volume changed: 4.5 µL; 4.8 µL; 5.0 µL and 5.2 µL of the well-mixed Marker mix put into differ-
ent wells on one chip with 1 µL of positive control. The measurement was repeated three times on different chips. 
c) Inter-Multi PCR repeatability: Multi-PCR with one positive control from AdnaTest ProstateCancerDetect kit was run in three sepa-
rate test tubes in the same thermo cycler run using the same master mix. The concentration of each PCR product was measured in 
three different wells on one chip. 
d) Inter-Multi PCR reproducibility: One positive control from the AdnaGen ProstateCancerDetect kit was used in six different Multi-
PCRs run, measured on six different chips. 
e) Repeatability: Three different samples (frozen after Multi-PCR) were measured in triplets on one chip. 
f) Reproducibility: Twelve cDNA samples (obtained after RT) frozen for 10 months were thawed. The Multi-PCR was repeated. New 
PCR products (1B-12 after 10 months) were measured on one chip. Frozen mixtures of these samples generated by the first Multi-PCR 
were re measured on the second chip (1A-12 after 10 months) and compared with the previous results (1A-12). 
The difference between the average sizes of the 
PCR fragments determined by our measurement 
and the data quoted by the manufacturer (Table 1) 
was lower than 3% (13).
The repeatability of PCR fragment 
concentration determination
Positive control
The RSD of the concentration determination was 
established based on the twelve measurements of 
one positive control (Figure 2). The RSD was under 
15% and after the normalization it was decreased 
to 5% (Table 2). By the normalization of the con-
centrations we discovered that DNA fragments in 
the positive controls were in a consistent ratio af-
ter the Multi-PCR: Actin 24%, EGFR 49%, PSA 18%, 
PSMA 10% (± 3).
Patient samples
The repeatability was established based on three 
patient samples measurement in triplicates. The 
average RSD of the PCR fragments with a concen-
tration over 0.3 ng/µL was 17 ± 3% and 2 ± 2% be-
fore and after the normalization respectively. The 
RSDs for the borderline results (concentration be-
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Table 1. The obtained average sizes of specific PCR fragments for control and patient samples measured during the two years re-
search by the Agilent DNA 1000 kit on the 2100 Bioanalyzer in order to obtain presence of CTCs - precision study.
Positive controls Patient samples All results 






size [bp] SD [bp] RSD
average 
size [bp] SD [bp] RSD
average 
size [bp] SD [bp] RSD
Actin 120 117 1 0.81% 117 1 1.25% 117 1 1.16%
EGFR 163 163 1 0.77% 163 2 1.00% 163 1 0.84%
PSA 357 357 2 0.68% 356 3 0.96% 356 3 0.88%
PSMA 449 444 6 1.29% 442 6 1.45% 443 6 1.37%
bp - base pair; SD - standard deviation; RSD - relative standard deviation; EGFR - epithelial growth factor receptor; PSA - prostate 
specific antigen; PSMA - prostate specific membrane antigen
*Not all samples from patients contained all monitored fragments. Only Actin as a control fragment was present in each measurement. 
Consequently, the number of measurements is different for each fragment: NActin = 101, NEGFR = 15, NPSA = 69, NPSMA = 31. The number 
of measurements is higher than the total number of patients since some of the samples were measured several times.
† The number of measurements is the sum of NPositive controls and NActin/EGFR/PSA/PSMA. 
Table 2. The average concentration of specific PCR fragments obtained by repeated measurement (N = 12) of one positive control 
sample on one Agilent DNA 1000 chip.
Obtained concentrations of positive control 
measurements before normalization
Obtained concentrations of positive control 
measurements after normalization
PCR fragment type Average concentration [ng/µL] SD   [ng/µL] RSD
Average 
concentration [none] SD   [none] RSD
Actin 2.89 0.29 10% 0.27 <0.01 2%
EGFR 5.54 0.48 9% 0.51 0.01 1%
PSA 1.77 0.21 12% 0.16 0.01 3%
PSMA 0.64 0.05 7% 0.06 <0.01 5%
bp - base pair; SD - standard deviation; RSD - relative standard deviation; EGFR - epithelial growth factor receptor; PSA - prostate 
specific antigen; PSMA - prostate specific membrane antigen.
Figure 2. Baseline record of the whole Agilent DNA 1000 chip analysis on 2100 Bioanalyzer. Ladder well is measured first followed by 
12 wells filled with the same positive control. The fluorescence intensity is decreasing during the measurement. 
L - ladder, 1C +…12C + - 12 measurements of one positive control.
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Table 3. The concentration of patient samples (N = 3) measured in triplets on one Agilent DNA 1000 chip. The comparison of differ-
ences (RSDs) between measured concentration before and after the normalization.
Obtained concentrations of patient samples 
before normalisation
Obtained concentrations of patient samples 
after normalisation
C1 [ng/µL] C2 [ng/µL] C3 [ng/µL] RSD C1 [none] C2 [none] C3 [none] RSD
Sample ID 39 39
Actin 3.98 3.05 3.12 15% 0.28 0.29 0.27 3%
EGFR 0.12 0.09 0.08 22% 0.01 0.01 0.01 11%‡
PSA 8.87 6.54 7.34 16% 0.63 0.62 0.64 2%
PSMA 1.09 0.81 0.87 16% 0.08 0.08 0.08 1%
Sample ID 52 52
Actin 3.78 5.64 3.87 24% 0.22 0.23 0.21 4%
EGFR 0.20 0.25 0.11 38% 0.01 0.01 0.01 31%‡
PSA 13.02 17.89 13.84 17% 0.76 0.74 0.77 2%
PSMA 0.19 0.32 0.21 29% 0.01 0.01 0.01 10%‡
Sample ID 58 58
Actin 2.42 1.81 2.72 20% 0.29 0.27 0.29 5%
EGFR 0.12 0.08 0.11 20% 0.01 0.01 0.01 12%‡
PSA 5.54 4.66 6.22 14% 0.67 0.69 0.67 2%
PSMA 0.21 0.21 0.22 3% 0.03 0.03 0.02 14%‡
bp - base pair; RSD - relative standard deviation; EGFR - epithelial growth factor receptor; PSA - prostate specific antigen; PSMA - 
prostate specific membrane antigen; C1,2,3 – PCR fragment concentration measured in the 1st, 2nd and 3rd measurement. 
‡ indicates borderline (0.15 - 0.3 ng/µL) concentration of the PCR fragment.
tween 0.15-0.3 ng/µL) were from 3% to 38% and 
from 10 to 31% before and after the normalization 
respectively (Table 3). These results are marked 
with stars in Table 3. After the normalization the 
highest RSDs remained in the PCR fragments with 
the borderline concentrations. 
The robustness of PCR fragment 
concentration determination
The robustness study was performed by measure-
ment of different volume of positive control (0.8-
1.1 μL) in the different well position (1-8) (Figure 
3a). The average RSD of the measurements of all 
four PCR fragments in all positions was 17 ± 2%. 
After the normalization the RSD decreased below 
4%. No decreasing trend in the concentration de-
termination was observed in the wells 5-8 in com-
parison with the wells 1-4 with the same sample 
volume.
The experiment with the changed Marker mix vol-
ume from 4.5 to 5.2 µL resulted in an average RSD 
of 9 ± 3% (Figure 3b). After the normalization the 
RSD fell to under 2%. 
The repeatability and reproducibility of PCR frag-
ment concentration determination after Multi-PCR 
repetition
Positive control
In the inter-Multi-PCR repeatability analysis the av-
erage RSD was 19 ± 10% before and 11 ± 8% after 
the normalization. For the inter-Multi PCR repro-
ducibility, the average RSD was 37 ± 16% before 
and 18 ± 11% after the normalization.
Patient samples
The reproducibility in time (10 months) was stud-
ied for cDNA and Multi-PCR product storage. Al-
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Figure 3. The obtained average concentrations (with SD) of specific PCR fragments measured in positive control for (a) different 
sample volumes (0.8-1.1 µL) and well locations (well number 1-8) (b) different Marker mix volumes (4.5-5.2 µL) - Robustness study.
EGFR - epithelial growth factor receptor; PSA - prostate specific antigen, PSMA - prostate specific membrane antigen
though the evaluation of results as positive/bor-
derline/negative was consistent even after long 
storage, the average RSD of the results was 40 ± 
20% before and 21 ± 20% after the normalization. 
There was a significant decrease in the concentra-
tion between the original and the repeated Multi-
PCR results (Figure 4). The average RSD for the 
original and the second measurement of the prod-
ucts from the same Multi-PCR was 17 ± 14% before 
and 7 ± 6% after the normalization. 
Figure 4. Overlaid electropherograms of two patient samples measured after the original Multi-PCR (a), the 10 months storage of 
original Multi-PCR product (b) and the repeated Multi-PCR (c) for two different samples. The time between the original and the sec-
ond Multi-PCR/measurement was 10 months for both samples. 
EGFR - epithelial growth factor receptor; PSA - prostate specific antigen; PSMA - prostate specific membrane antigen.
The influence of magnetic beads presence on 
the measurement on the Agilent DNA 1000 
platform
During the measurements on 2100 Bioanalyzer 
due to the transfer of magnetic beads form the 
sample to the chip, specific peaks, called spikes 
may appear (18). Sometimes, they can influence 
the measurement by interfering with the upper 
marker. These specific peaks appeared several 
times during our measurements. Results are 
shown in Figure 5.
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Discussion
The analysis of the data collected throughout two 
years of research combined with the additional ex-
periments gave us a picture of the characteristics 
of the PCR fragment analysis by the Agilent 1000 
DNA kit on the 2100 Bioanalyzer. 
The PCR fragment size determination gave very 
satisfactory results. The RSD was up to 2% and 
there was no difference between the samples and 
positive controls (Table 4). The standard deviation 
(SD) of the size determination slowly increases 
with increasing length of the PCR fragments (Table 
1). It results from the principle of the electrophore-
sis - the longer the fragment the lower the resolu-
tion. The trueness of PCR fragment size determina-
tion was under 3%.
Figure 5. Spike overlapping with the upper marker observed 
in one patient sample measurement. The change in the upper 
marker peak area influences the concentration determination 
of PCR fragment (Actin) in this sample. Lower and upper mark-
ers are present in each well and enable the PCR fragment size 
and concentration determination.



















31 under 2% - Table 1
Trueness 31 under 3% - Table 1
Precision Patient 
samples
101§ under 2% - Table 1
Trueness 101 under 3% - Table 1
Obtained 
characteristics 






12 15% 5% Table 2
Robustness
Sample volume 3 × 8 17 ± 2% 2 ± 1% Figure 3a
Marker mix 
volume 3 × 4 9 ± 3% 1 ± 1% Figure 3b
Inter Multi-PCR Repeatability 3 × 3 19 ± 10% 11 ± 8% Not shown




3 × 3 17 ± 3% 2 ± 2% Table 3
Reproducibility for PCR product 
storage║ 1 × 1 × 12 17 ± 14% 7 ± 6% Figure 4
Reproducibility for cDNA storage║ 1 × 1 × 1 × 12 40 ± 20% 21 ± 20% Figure 4
CTC - circulating tumour cell; PCR – polymerase chain reaction; RSD - relative standard deviation
§Not all samples from patients contained all monitored fragments. Only Actin as a control fragment was present in each measurement. 
Consequently, the number of measurements is different for each fragment: NActin = 101, NEGFR = 15, NPSA = 69, NPSMA = 31. The number 
of measurements is higher than the total number of patients since some of the samples were measured several times.
║Samples were stored for 10 months in -20 °C. 
Table 4. Summary of all method characteristics determined in the study based on the results obtained from the two years CTC re-
search (PCR fragment size measurement) and additional experiments (PCR fragment concentration measurement).
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Small differences between the predicted sizes of 
the PCR fragments and the average sizes obtained 
from the measurements were mentioned in the 
previous studies (3,19). These can be caused by the 
small changes between standard curves of migra-
tion time versus DNA size which are determined 
from the DNA sizing ladder on each chip (20) or by 
the changes in the fluorescent dye binding which 
may affect the fragment mobility (21). Our results 
are in agreement with other studies, which also re-
ported the PCR fragment size determination by 
the Agilent as true and precise (7,8,11). However, to 
the best of our knowledge we are the first to have 
evaluated data from patient samples acquired dur-
ing a long-term project. The sizing trueness and 
precision measured on patient samples in our 
study are within the range stated by the manufac-
turer for the ladder as a sample (17).
The RSD of the concentration determination re-
peatability around 15% (Table 4) is consistent with 
Alberice et al. (22). It also confirms on the patient 
samples the manufacturer’s data which were 
measured with the ladder as a sample (17). After 
the normalization we can compare the ratio of in-
dividual markers in the sample. Since the normali-
zation significantly reduces the RSD (Table 2) we 
know that the differences in the concentrations 
between different wells are proportional. That 
proportional error could be generated by manual 
pipetting required during the loading of the chip. 
According to our experiment with method robust-
ness the change in sample volume influences the 
resulting concentration (Figure 3a). When the vol-
ume of the Marker mix is changed, the concentra-
tion of the DNA fragments is, as expected, inverse-
ly proportional to the quantity of the Marker mix 
in the well (Figure 3b). However, even these chang-
es in tens of percent in sample or Marker mix vol-
ume do not lead to an RSD much higher than the 
15%, which is present in normal measurement. Un-
like in previous work (8), results of our study indi-
cate that the manual pipetting is not the main 
cause of the 15% variance in concentration deter-
mination, otherwise such major pipetting errors 
have to be present in every chip preparation pro-
cedure.
A continual decrease and deterioration of the sig-
nal observed during our measurements was also 
considered to be a possible cause of this 15% vari-
ance (Figure 2). The baseline decrease can be 
caused by a decrease in fluorescent dye concen-
tration caused by its constant migration toward 
the waste well or by its photo bleaching caused by 
the laser beam. Since there is only one detection/
separation channel on the chip this could be also 
one reason for a worsening baseline (16,23). The 
dedicated measurements did not prove the im-
pact of the well position on the concentration de-
termination (Figure 3a). Despite the fact that the 
difference in sample migration times on one chip 
follow one pattern (15) the changes in sample con-
centration within one chip seem to be irregular 
and differ between the chips. As showed by the 
normalization the 15% variation is a proportional 
error. The data for the Bioanalyzer shows that the 
changes in concentration are connected with the 
change in the sample/marker signal ratio. In our 
view, this change can be generated by the princi-
ple of the sample injection to the detection/sepa-
ration channel (2,23). Based on this assumption, 
the concentration variation within 15% cannot be 
eliminated by the user. 
For the concentration determination repeatability, 
the RSDs in the patient samples are higher than 
RSDs in the positive controls because of the pres-
ence of the low concentration PCR fragments. The 
repeatability of the quantification of PCR frag-
ments in a concentration under 0.3 ng/µL is poor 
(Table 3.). The measurement is influenced by noise, 
baseline vibration and Multi-PCR conditions. If PCR 
fragments are present only in these concentra-
tions, the manufacturer recommends retesting the 
patient after a few weeks because of the high 
probability of false results (13). One clarification 
option is to repeat the Multi-PCR several times and 
statistically evaluate the results.
As expected, the differences in PCR fragment con-
centration between the separate Multi-PCRs were 
higher than those of the intra-Multi PCR. This may 
have been caused by minute differences in PCR 
conditions and reaction efficiency. However, the 
average RSD fewer than 30% before and 20% after 
the normalization may be considered acceptable. 
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For the positive control inter-Multi PCR reproduci-
bility, the slight differences in master mix and sub-
tle variations in PCR conditions, even if a validated 
thermo cycler and calibrated pipettes are used, 
have to be taken into account. Also the use of dif-
ferent chips, the storage and the repeated freez-
ing and thawing of the positive control can play a 
role. The high RSD measured in the inter-Multi-
PCR experiment showed that the long storage of 
single-stranded cDNA at -20 °C may lead to its 
degradation. The degradation of the samples dif-
fers from sample to sample (Figure 4). A small shift 
in the peak position is present because the DNA 
fragment migration is calculated for each chip and 
may marginally differ (20). The Multi-PCR repeated 
with the stored cDNA results in different PCR frag-
ment concentration than the original Multi-PCR. 
Interestingly, the RSD remained at about 20% even 
after the normalization (Table 4). This indicates 
that the storage also influenced the proportional 
representation of the PCR fragments in the Multi-
PCR product. The manufacturer advises against 
storing the cDNA for more than four weeks (14). 
On the other hand, double-stranded PCR frag-
ments originating from Multi-PCR can be success-
fully measured again even after several months of 
storage. To conclude, the RSD of the PCR fragment 
concentration determination increases with every 
additional analytical/storage step added between 
the two measurements (Table 4).
Finally, we would like to highlight our experience 
of spikes, which appeared several times during our 
measurements. They can be cause by the pres-
ence of magnetic beads in the sample, against 
which the manufacturer warns (17). The problem 
may arise when spike interfere with the upper 
marker (Figure 5) from which the concentration 
determination of PCR fragments is derived. In that 
case the repeated measurement of the sample on 
2100 Bioanalyzer is necessary. From our two years 
experience the beads in the sample usually do not 
cause major problems. However, it is better to re-
tain them in a PCR-tube by use of a magnetic hold-
er when sample is put on the chip to prevent the 
necessity of measurement repetition.
In conclusion, the Agilent DNA 1000 kit used on 
2100 Bioanalyzer represents a useful tool for de-
termining the size and concentration of PCR frag-
ments. In particular, the size determination is true 
and precise even for the data acquired during a 
long-term project. As regards concentration deter-
mination, it is necessary to anticipate a result varia-
tion of up to 15% and for the concentrations be-
low 0.3 ng/µL even higher variation. In the Multi-
PCR analysis, an important thing to be taken in ac-
count is the possible influence of the storage of 
cDNA as well as mRNA on the results. We suggest 
future users of this method to think about the pos-
sibility of evaluating results based on relative rath-
er than on the absolute concentration of PCR frag-
ments, especially for those cases in which compar-
ison between the samples is more important than 
the precise concentration. 
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